Crinetics Pharmaceuticals Ownership
| CRNX Stock | USD 35.94 1.52 4.42% |
Shares in Circulation | First Issued 2017-03-31 | Previous Quarter 80 M | Current Value 81 M | Avarage Shares Outstanding 35.7 M | Quarterly Volatility 24.5 M |
Crinetics |
Crinetics Stock Ownership Analysis
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Crinetics Pharmaceuticals was currently reported as 14.26. The company recorded a loss per share of 3.69. Crinetics Pharmaceuticals had not issued any dividends in recent years. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Crinetics Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 143 people. For more info on Crinetics Pharmaceuticals please contact Scott Struthers at 858 450 6464 or go to https://www.crinetics.com.Crinetics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Crinetics Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Crinetics Pharmaceuticals backward and forwards among themselves. Crinetics Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Crinetics Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jennison Associates Llc | 2024-12-31 | 2.7 M | Geode Capital Management, Llc | 2024-12-31 | 2.1 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.9 M | Siren, L.l.c. | 2024-12-31 | 1.6 M | Franklin Resources Inc | 2024-12-31 | 1.6 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 1 M | Cormorant Asset Management, Llc | 2024-12-31 | 1000 K | Orbimed Advisors, Llc | 2024-12-31 | 999 K | Novo A/s | 2024-12-31 | 960.2 K | Vanguard Group Inc | 2024-12-31 | 9.1 M | Fmr Inc | 2024-12-31 | 8.9 M |
Crinetics Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crinetics Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crinetics Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Crinetics Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Crinetics Pharmaceuticals' latest congressional trading
Congressional trading in companies like Crinetics Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Crinetics Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
| 2024-10-03 | Representative Josh Gottheimer | Acquired Under $15K | Verify |
Crinetics Pharmaceuticals Outstanding Bonds
Crinetics Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Crinetics Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Crinetics bonds can be classified according to their maturity, which is the date when Crinetics Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Crinetics Pharmaceuticals Corporate Filings
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 5th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 27th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.